文献速递脑血管病

氯吡格雷联合阿司匹林双联抗血小板治疗与阿司匹林单药治疗急性非轻型卒中的比较有效性:全国多中心登记研究

Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Acute, Nonminor Stroke: A Nationwide, Multicenter Registry-Based Study.
PubMed 文献 · Stroke · 2019-10-07

本研究基于全国多中心卒中登记数据库,纳入发病24小时内、基线NIHSS评分4-15分的急性非心源性栓塞性卒中患者4461例,采用倾向评分逆概率加权比较氯吡格雷联合阿司匹林双联抗血小板治疗(DAPT)与阿司匹林单药治疗(AM)的有效性。主要终点为3个月内所有类型卒中、心肌梗死和全因死亡的复合终点,DAPT组与AM组无显著差异(20.9% vs 22.6%,P=0.13),但DAPT组全因死亡率显著低于AM组(3.4% vs 4.9%,P=0.02)。

要点

  • 急性非轻型非心源性卒中3个月内复合终点DAPT与AM无显著差异。
  • DAPT组全因死亡率显著低于AM组(3.4% vs 4.9%,P=0.02)。
  • 中重度责任动脉狭窄及NIHSS 12-15分亚组可能从DAPT获益。

核心结论

  • 与阿司匹林单药相比,氯吡格雷联合阿司匹林未降低非轻型非心源性缺血性卒中后3个月内复合终点事件风险。

研究设计与样本

  • 基于前瞻性全国多中心卒中登记数据库,纳入发病24小时内、基线NIHSS评分4-15分的急性非心源性栓塞性卒中患者4461例,采用倾向评分逆概率加权调整基线差异。

主要发现

  • 主要复合终点事件DAPT组20.9% vs AM组22.6%,P=0.13,无显著差异。
  • 所有类型卒中事件率DAPT组19.3% vs AM组20.1%,P=0.35,无显著差异。
  • 全因死亡率DAPT组3.4% vs AM组4.9%,P=0.02,DAPT组显著降低。
  • 倾向加权Cox模型显示DAPT未降低主要终点风险(HR 0.91,95%CI 0.79-1.04),但降低全因死亡风险(HR 0.69,95%CI 0.49-0.97)。
  • 预设亚组无治疗异质性,但中重度责任动脉狭窄及NIHSS 12-15分亚组提示DAPT潜在获益。

关键数值与推荐

  • 主要复合终点定义为3个月内所有类型卒中(缺血性和出血性)、心肌梗死和全因死亡的复合终点。

临床怎么用

  • 对于急性非轻型非心源性缺血性卒中患者,DAPT未显著减少复合终点事件,但可能降低全因死亡风险,需个体化评估获益与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- This study aimed to compare the effectiveness of dual antiplatelet therapy with clopidogrel plus aspirin (DAPT) with that of aspirin monotherapy (AM) in patients with acute, nonminor, and noncardioembolic stroke. Methods- Using a prospective, nationwide, multicenter stroke registry database, acute (within 24 hours of onset), nonminor (baseline National Institutes of Health Stroke Scale score, 4-15), and noncardioembolic stroke patients were identified. Propensity scores using inverse probability of treatment weighting were used to adjust baseline imbalances between the DAPT and AM groups. A primary outcome measure was a composite of all types of stroke (ischemic and hemorrhagic), myocardial infarction, and all-cause mortality within 3 months of stroke onset. Results- Among the 4461 patients meeting the eligibility criteria (age, 69±13 years; men, 57.7%), 52.5% (n=2340) received AM, and 47.5% (n=2121) received DAPT. The primary outcome event was not significantly different between the DAPT group and the AM group (20.9% versus 22.6%, P=0.13). The event rates of all types of stroke were also not different between the 2 groups (19.3% versus 20.1%, P=0.35), while all-cause mortality was significantly lower in the DAPT group than in the AM group (3.4% versus 4.9%, P=0.02). In the propensity-weighted Cox proportional hazards models with robust estimation, DAPT did not reduce the risk of the primary outcome event (hazards ratio, 0.91; 95% CI, 0.79-1.04) but did reduce the risk of all-cause mortality (0.69; 0.49-0.97). There was no treatment heterogeneity among the predefined subgroups, although the potential benefits of DAPT were suggested in subpopulations of moderate-to-severe relevant arterial stenosis and relatively severe deficits (National Institutes of Health Stroke Scale score, 12-15). Conclusions- Compared to AM, clopidogrel plus aspirin did not reduce the risk of the primary outcome event during the first 3 months after a nonminor, noncardioembolic, ischemic stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kim JT, Park MS, Choi KH, et al. Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Acute, Nonminor Stroke: A Nationwide, Multicenter Registry-Based Study. Stroke. 2019. PMID: 31587655. doi:10.1161/STROKEAHA.119.026044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。